Monoamine Uptake Inhibitors | Dopamine/Norepinephrine Reuptake Inhibitors | Monoamine Oxidase Inhibitors | Drugs With Mixed Pharmacological Properties
Inhibition of monoamine reuptake at presynaptic nerve terminals
defines this drug group. It includes the tricyclic antidepressants
(TCAs), the selective serotonin reuptake inhibitors (SSRIs), and
the mixed-uptake inhibitors with minimal receptor-blocking properties
(e.g., venlafaxine, duloxetine). Older drugs in this group tend
to be pharmacologically nonselective and often have active metabolites.
The newer drugs (e.g., SSRIs, venlafaxine) tend to be more selective
for reuptake blockade and have fewer side effects.